Handok Inc., has entered into a Supply and Distribution agreement with Incyte (NASDAQ:INCY) to, upon regulatory approvals, launch and distribute tafasitamab (sold as Monjuvi^® in the United States and Minjuvi^® in Europe) and pemigatinib (Pemazyre^®) in South Korea. Under the terms of agreement, Handok will be responsible for seeking approval reimbursement listing and the exclusive distribution of both medicines in South Korea.

Tafasitamab in combination with lenalidomide is approved in the United States and Europe for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).  In December 2021, tafasitamab received Orphan Drug Designation from the Korean Ministry of Food and Drug Safety.

Pemigatinib is approved in the United States, Europe and Japan for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Pemigatinib received Orphan Drug Designation from the Korean Ministry of Food and Drug Safety in November 2021

Young-Jin Kim, President of Handok, said “We are pleased to partner with Incyte and, if approved, offer these innovative therapies to patients in Korea who currently have no other treatment options for their cancers. We remain committed to improving and providing treatments for cancer patients as we are driven by our commitment to the oncology community.”